Erratum: Morillo-Gutierrez B, Beier R, Rao K, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: A multicenter experience (Blood (2016) 128:3 (440-448) DOI: 10.1182/blood-2016-03-704015);Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: A multicenter experience

Blood

Volumn 128, Issue 3, 2016, Pages 440-448

  Morillo Gutierrez, Beatriz ^a   Beier, Rita ^b   Rao, Kanchan ^c   Burroughs, Lauri ^d,e   Schulz, Ansgar ^f   Ewins, Anna Maria ^g   Gibson, Brenda ^g   Sedlacek, Petr ^h   Krol, Ladislav ^h   Strahm, Brigitte ⁱ   Zaidman, Irina ^j   Kalwak, Krzysztof ^k   Talano, Julie An ^l   Woolfrey, Ann ^d,e   Fraser, Chris ^m   Meyts, Isabelle ⁿ   Müller, Ingo ^o   Wachowiak, Jacek ^p   Bernardo, Maria Ester ^q   Veys, Paul ^c   Sykora, Karl Walter ^b   Gennery, Andrew R ^a,r   Slatter, Mary ^a,r   more..

^a Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d USA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j RAMBAM MEDICAL CENTER   (Israel)

^k WROCLAW MEDICAL UNIVERSITY   (Poland)

^l MEDICAL COLLEGE OF WISCONSIN   (United States)

^m LADY CILENTO CHILDREN S HOSPITAL   (Australia)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^q SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^r NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; CD3 ANTIGEN; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; BUSULFAN;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANUS DISEASE; ARTICLE; ASPERGILLOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AVASCULAR NECROSIS; CHILD; CHILDHOOD MORTALITY; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENERALIZED EPILEPSY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HIGH RISK PATIENT; HLA MATCHING; HLA SYSTEM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MYOPATHY; NEUROTOXICITY; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; PERIANAL ULCERATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; ULCER; VIRUS REACTIVATION; ACUTE DISEASE; ALLOGRAFT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GRAFT SURVIVAL; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; METABOLISM; MORTALITY; MULTICENTER STUDY; PROCEDURES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOGRAFTS; BLOOD PLATELETS; BUSULFAN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEUTROPHILS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84979529945     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-10-745455     Document Type: Erratum

References (25)

1. Goldblatt D. Recent advances in chronic granulomatous disease. J Infect.2014;69(Suppl 1):S32-S35.
2. Marciano BE, Spalding C, Fitzgerald A, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176-1183.
3. Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008;152(2):211-218.
4. Cole T, Pearce MS, Cant AJ, Cale CM, Goldblatt D, Gennery AR. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;132(5):1150-1155.
5. Salvator H, Mahlaoui N, Catherinot E, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. Eur Respir J. 2015;45(6):1613-1623.
6. Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 2009;145(1):73-83.
7. Seger RA. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am. 2010;30(2):195-208.
8. Cole T, McKendrick F, Titman P, et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol. 2013;33(1):8-13.
9. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 2002;100(13):4344-4350.
10. Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344(12):881-888.
11. Segal BH, Veys P, Malech H, Cowan MJ. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant. 2011;17(1 Suppl):S123-S131.
12. Chiesa R, Veys P. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol. 2012;8(3):255-267.
13. Güngör T, Teira P, Slatter M, et al; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436-448.
14. Slatter MA, Boztug H, Pötschger U, et al; EBMT Inborn Errors and Paediatric Diseases Working Parties. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50(12):1536-1541.
15. Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117(16):4367-4375.
16. Burroughs LM, Nemecek ER, Torgerson TR, et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow Transplant. 2014;20(12):1996-2003.
17. Boztug H, Zecca M, Sykora KW, et al; EBMT paediatric diseases working party. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol. 2015;94(2):297-306.
18. Mathews V, George B, Viswabandya A, et al. Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One. 2013;8(4):e61637.
19. ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014;19(10):1572-1586.
20. Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21(2):251-257.
21. Klaudel-Dreszler MA, Kalwak K, Kurenko-Deptuch M, et al. Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. Int J Hematol. 2009;90(5):571-575.
22. Oshrine B, Morsheimer M, Heimall J, Bunin N. Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease. Pediatr Blood Cancer. 2015;62(2):359-361.
23. Marsh RA, Lane A, Mehta PA, et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood. 2016;127(4):503-512.
24. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105(2):879-885.
25. Panasiuk A, Nussey S, Veys P, et al. Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan. Br J Haematol. 2015;170(5):719-726.